Zogenix, Inc. (ZGNX) Posts Positive Phase 4 Results for Migraine Treatment

QualityStocks would like to highlight Zogenix, Inc. (NASDAQ: ZGNX). With offices in San Diego and Emeryville, California, Zogenix is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL(R) DosePro(TM) (sumatriptan injection) Needle-free Delivery System, was launched in January 2010, for the acute treatment of migraine and cluster headache.

In the company’s news yesterday,

Zogenix reported clinical data from its phase 4 open-label, multicenter study of SUMAVEL® DosePro ® Needle-free Delivery System for the treatment of migraines.

The company demonstrated the clinical data in two poster presentations at the 63rd Annual Meeting of the American Academy of Neurology (AAN) in Honolulu, Hawaii.

“The clinical findings of this phase 4 study indicate that patients showed a greater Overall Satisfaction with subcutaneous sumatriptan delivered by SUMAVEL DosePro than their current triptan therapy, which was predominantly oral dosage forms. SUMAVEL DosePro improves upon traditional needle-based sumatriptan injection therapy by providing convenience and ease of use in a needle-free delivery system, and may be a useful therapeutic option when rapid onset of efficacy is important in relieving migraine pain and symptoms,” Stephen J. Farr, Ph.D., president and chief operating officer of Zogenix stated in the press release.

John F. Rothrock, M.D., director of the University of Alabama School of Medicine Headache Treatment and Research Program and co-author of the phase 4 study, said the results demonstrate that SUMAVEL DosePro showed an increased rate of lasting relief from migraine symptoms.

“Coupled with the ease of use and rapid onset of action, needle-free SUMAVEL DosePro should be viewed as an attractive addition to the toolbox of migraine therapeutics for patients treating their migraines of moderate to severe intensity,” Dr. Rothrock stated.

The first poster presentation reported on treatment satisfaction, while the second poster presentation reported on the efficacy and tolerability of SUMAVEL DosePro among current triptan users over multiple migraine attacks.

Zogenix and its co-promotion partner Astellas Pharma US, Inc. launched SUMAVEL DosePro in the United States in January 2010.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.